Navigation Links
US Oncology Reports Fourth Quarter and Fiscal Year 2007 Results
Date:2/28/2008

es and Risks

During the fourth quarter of 2005, we received a subpoena from the United States Department of Justice's Civil Litigation Division ("DOJ") requesting a broad range of information about us and our business, generally in relation to our contracts and relationships with pharmaceutical manufacturers. We are cooperating fully with the DOJ in responding to the subpoena. At the present time, the DOJ has not made any allegation of wrongdoing on the part of the Company. We cannot, however, provide assurance that such an allegation or litigation will not result from this investigation.

On April 18, 2006, the Company terminated its net revenue model comprehensive service agreement with a practice in Oklahoma, as a result of alleged breaches of that agreement by the practice. The practice accounted for 4.6 percent and 2.3 percent of the Company's revenue and EBITDA, respectively, for the first quarter of 2006. The Company remains in litigation with this practice regarding termination of its service agreement. As a result of the practice's alleged breaches of that agreement and the litigation, we were unable to collect payments on receivables owned by us and other amounts owed by the practice on a timely basis. At December 31, 2007, the total amount owed to us for those receivables of $22.5 million is reflected on our balance sheet as other assets. We intend to pursue the claims we incurred as a result of terminating this service agreement. We also intend to defend against the practice's allegations that we breached the agreement and that the agreement is unenforceable. As with any complex litigation, the process necessary to resolve this claim may take several years.

During March 2007, the Company became aware that it and one of its affiliated practices are the subject of allegations that the practice may have engaged in activities that violate the Federal False Claims Act. These allegations are contained in a qui tam complaint, commonly referr
'/>"/>

SOURCE US Oncology Holdings, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26

Related biology technology :

1. Six UK Hospitals Join Together in Using Varian Medical Oncology Information Network
2. Genstruct CEO, Dr. Keith Elliston, Invited to Speak at Oncology Clinical Trial Summit
3. Founder of ILEX Oncology and Triton Biosciences, Richard Love, Joins Board of Directors of Cell Therapeutics, Inc. (CTI)
4. Ranbaxy to Consolidate Position in Biopharmaceuticals and Speciality Injectables Including Oncology
5. Pharsight Invited to Present on Oncology Modeling and Simulation at Quantitative Pharmacology Symposium in China
6. PRA International to Present Audioconference on Oncology Research - Nov. 8
7. IMPAC Medical Systems to Offer Revenue Cycle Inc.s Array of Oncology Products and Services to Customers
8. AG Mednet to Provide Image Network for Southwest Oncology Group
9. Quest PharmaTech to Receive $3,000,000 to Develop Oncology Products Based on its SonoLight Technology
10. Center for Molecular Medicine Selected to Provide DNA Analysis for Childrens Oncology Group Leukemia Study
11. Oncology Metrics and Cureline Announce Joint Marketing Agreement
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... On Wednesday of last week RENU 28, the world's first ... available for purchase in Australia and New Zealand, and the ... works is, if you think about the definition of aging, ... renewal within your body. If you think about the definition ... renewal. What RENU 28 does is it works with these ...
(Date:8/20/2014)... Neurotrope, Inc. (OTCQB: NTRP) today announced ... provide an update on Company activities. Access information:Date:Tuesday, ... 505-4369 (U.S. and Canada) or (719) 325-2315 Conference ... under "Investor Relations"The teleconference replay will be available ... 2014 at (888) 203-1112 (U.S. and ...
(Date:8/20/2014)... August 20, 2014 Not long ago, ... studies should be performed late in the development cycle ... But current regulatory trends suggest that, like many things ... rise. In recent years, multiple drug sponsors have been ... address specific questions during phase I/II. It’s not only ...
(Date:8/19/2014)... (PRWEB) August 20, 2014 One ... regenerative medicine is an inadequate vascular supply. Nutrient ... and decellularized tissues is critical for successful regeneration ... attempted to mitigate deficiencies in vascularization and promote ... scaffold bioactivity, optimizing scaffold design and architecture, and ...
Breaking Biology Technology:RENU 28 Skin Care Now Available in Australia and New Zealand 2Neurotrope To Host Conference Call 2Are Extractable and Leachables going Phase-Appropriate? New Webinar Hosted by Xtalks 2Vascularization in Tissue Engineering Highlighted at 12th New Jersey Symposium on Biomaterials Science 2
... Calif., Oct. 12, 2011 Life Technologies ... announced the Applied Biosystems QuantStudio™ 12K Flex ... that enables cost-effective and efficient interrogation of hundreds of ... run. The growing demand of biomarker screening ...
... The National Science Foundation (NSF) has selected a University ... class of NSF Innovation Corps awards. The I-Corps Awards ... and connects scientists to entrepreneurial resources. "The idea ... intellectual property from the lab into the commercial world," ...
... 11, 2011 ThermoGenesis Corp. (NASDAQ: KOOL ... that process and store adult stem cells, said today ... (AXP) which is used to concentrate stem cells from ... & Drug Administration (SFDA) in China. This represents the ...
Cached Biology Technology:Life Technologies Announces Flagship PCR Instrument that Enables Cost-Effective, High-Throughput Screening Applications 2Life Technologies Announces Flagship PCR Instrument that Enables Cost-Effective, High-Throughput Screening Applications 3Life Technologies Announces Flagship PCR Instrument that Enables Cost-Effective, High-Throughput Screening Applications 4Penn team wins entrepreneurial innovation award 2ThermoGenesis Announces Acceptance of AXP® Submission by Regulatory Body in China 2ThermoGenesis Announces Acceptance of AXP® Submission by Regulatory Body in China 3
(Date:8/20/2014)... scientists have discovered that acral melanomas the rare type ... are genetically distinct from other more common types of ... in the journal Pigment Cell & Melanoma Research . ... hands, soles of the feet, nail-beds and other hairless parts ... it,s not caused by UV damage from the sun. , ...
(Date:8/20/2014)... plastic bags could one day be made out of ... are now reporting. The novel process they developed and ... its agricultural and plastic waste problems, appear in the ... S. Bayer and colleagues at the Italian Institute of ... In 2012, its production reached 288 million tons worldwide, ...
(Date:8/20/2014)... 1 (PS1) absorbs light and its energy is ... to biomass. Photovoltaic devices, mostly build from silicon ... electricity. One approach for the development of cheaper ... with the isolated membrane protein complexes of photosynthesis. ... stable PS1 from thermophilic cyanobacteria that live in ...
Breaking Biology News(10 mins):Scientists learn more about rare skin cancer that killed Bob Marley 2A semi-artificial leaf faster than 'natural' photosynthesis 2
... Journal of Experimental Biology are pleased to announce ... is the winner of this year,s JEB Outstanding Paper ... in The Journal of Experimental Biology at ... of an outstanding young scientist to an exceptional research ...
... A new and insidious environmental threat has been ... Queen,s and York universities. Along with scientists ... documented biological damage caused by declining levels of ... the phenomenon "aquatic osteoporosis," Queen,s PhD candidate Adam ...
... Cameroon, and other partners have collaborated to create a ... endangered great ape: the Cross River gorilla. The ... area with Nigeria,s Cross River National Park, safeguarding an ... populationalong with other rare species. Trans-boundary protected areas allow ...
Cached Biology News:French scientist wins the Journal of Experimental Biology Outstanding Paper Prize 2French scientist wins the Journal of Experimental Biology Outstanding Paper Prize 3Queen's University biologists find new environmental threat in North American lakes 2New national park protects world's rarest gorilla 2New national park protects world's rarest gorilla 3
Sf21 Insect Cells (Live) in Max-XP Medium...
... The BioGenex Super Sensitive ... is a novel product ... non-biotin polymeric technology. This ... signal to noise ratio ...
Artisan™ Wash Solution (x 50) Additional Information: EU regulatory status: CE US regulatory status: IVD ...
MiniCycler thermal cycler with Hot Bonnet heated lid, holds 25x0.2ml tubes...
Biology Products: